MA-VERACODE
6.10.2022 13:51:35 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform to include container security. This early access program for Veracode Container Security is now underway for existing customers. The new Veracode Container Security offering, designed to meet the needs of cloud-native software engineering teams, addresses vulnerability scanning, secure configuration, and secrets management requirements for container images.
Veracode Chief Product Officer, Brian Roche, said, “As developers embrace cloud-native computing practices, containers have become increasingly important for business efficiency. This launch helps close a substantial gap in the market for developer-friendly solutions that cover critical capabilities for container security. We are excited to bring this next enhancement of our platform to the market and empower customers to address security testing for more modern architectures and deployment styles.”
The Requirement for Container Security is Rapidly on the Rise
Containers are increasingly used to simplify software deployment and runtime environment configuration management. They comprise small, fast, portable units of software in which code is packaged so that an application can be run quickly and reliably in different computing environments—from the desktop to the cloud. They provide an ecosystem of repositories, orchestration technologies, and capabilities that address related issues, such as service-to-service communication and configuration management. Instantiated in pipelines from code, containers have the benefit of immutability, meaning they are not updated, reconfigured or patched in production. Instead, the underlying image is updated with new capabilities and redeployed, helping to improve efficiency in the production environment.
Despite the benefits of containers, they are affected by many of the same problems that traditionally plague physical production or virtual server hardware, such as vulnerabilities introduced through additional software, poorly managed secrets (like Amazon Web Services keys and credentials in Dockerfiles), and security misconfigurations. This has resulted in increased demand for products that address these issues and related problems, with the Global Container Security Market size expected to reach $3.9 billion by 2027*. Container security scanning analyzes container images against organizational or industry-specific standards to identify insecure processes, misconfigurations that could lead to a vulnerability, and inadequate authentication and access control.
Veracode Container Security Integrates into the Developer Environment
Many products already in the market are aimed at securing containers in runtime and offer limited support for developers, posing a major challenge for early remediation. Veracode’s solution instead integrates into the CI/CD (continuous integration and continuous delivery) pipeline and is available at the command line interface. Providing coverage for vulnerability detection and remediation, secrets management, and security configuration issues on the most popular operating systems, it delivers remediation advice to developers early in the software development life cycle so that insecure containers don’t ship to production.
Veracode Container Security results are available in a variety of formats based on the user’s choice, including text, JSON (JavaScript Object Notation), and Software Bill of Materials (CycloneDX, SWID [Software Identification Tagging], or SPDX [Software Packaging Data Exchange]), making them easy to integrate with other tools. Providing developers and their teams with the tools to meet their specific needs means they can find and fix vulnerabilities early in the lifecycle, giving them confidence that their containerized application environment is secure.
“Veracode Container Security will be instrumental for our developers to ensure that the workloads they deploy into our cloud are secure,” said the Director of Information Security at an automotive company. “Without this tool, it would take our team weeks to receive and action container results and these would only have been available in limited formats. Now, we’re excited to integrate findings into the pipeline before they even move into production, creating time and cost efficiencies for our business.”
To learn more about Container Security, read more here.
*Research and Markets, "Global Container Security Market Size, Share & Industry Trends Analysis Report By Component (Products and Services), By Services Type, By Organization Size, By Vertical, By Regional Outlook and Forecast, 2021-2027" report, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
